Human HSCs Transdifferentiated from MSCs can be Used for the Treatment of Blood Diseases and Fabrication of Blood
Conference Recording Jun 15, 2013
About the SpeakerDr. James Q. Yin, male, molecular biologist, gained his Ph.D. from cell biology department, Peiking Union Medical college in 1988. As a postdoctoral fellow and assistant professor, he worked for Bowman Gray Sch. of Med. from 1988 to 1993. After that time, he was employed as a faculty member in Harvard Medical School and MIT. Since 2003, he became a professor in Institute of Biophysics, CAS. His research interests are focused on RNAi technology and stem cell biology as well as their application for clinical therapy. He has successfully developed the first world’s commercialized product based on RNAi technology. Now he is working on the MSC-HSCs used for the treatment of leukemia and other diseases.
Our findings provide the first demonstration that transfection of two small RNAs (sRNA) for two days is sufficient to trigger adipose-derived mesenchymal stem cells (AD-MSCs) to transdifferentiate into hematopoietic stem cells (HSCs) in a large-scale level.